Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-Aoba, Aramaki, Aoba-ku, Sendai, 980-8578, Japan.
Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto, 862-0973, Japan.
Angew Chem Int Ed Engl. 2018 Apr 23;57(18):5147-5150. doi: 10.1002/anie.201801659. Epub 2018 Mar 22.
The total synthesis of siladenoserinol A, an inhibitor of the p53-Hdm2 interaction, has been achieved. AuCl -catalyzed hydroalkoxylation of an alkynoate derivative smoothly and regioselectively proceeded to afford a bicycloketal in excellent yield. A glycerophosphocholine moiety was successfully introduced through the Horner-Wadsworth-Emmons reaction using an originally developed phosphonoacetate derivative. Finally, removal of the acid-labile protecting groups, followed by regioselective sulfamate formation of the serinol moiety afforded the desired siladenoserinol A, and benzoyl and desulfamated analogues were also successfully synthesized. Biological evaluation showed that the sulfamate is essential for biological activity, and modification of the acyl group on the bicycloketal can improve the inhibitory activity against the p53-Hdm2 interaction.
已实现了 p53-Hdm2 相互作用抑制剂 siladenoserinol A 的全合成。AuCl 催化的炔酸酯衍生物的氢烷氧基化反应以优异的收率顺利且区域选择性地进行,得到双环缩酮。通过使用最初开发的膦酸酯衍生物的 Horner-Wadsworth-Emmons 反应成功引入了甘油磷酸胆碱部分。最后,通过酸不稳定保护基的脱保护,以及丝氨酸醇部分的区域选择性磺酰胺形成,得到了所需的 siladenoserinol A,并且还成功合成了苯甲酰基和去磺酰胺类似物。生物评价表明,磺酰胺对于生物活性是必需的,并且双环缩酮上的酰基修饰可以提高对 p53-Hdm2 相互作用的抑制活性。